Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lung Cancer
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
By
William King
ESMO
,
Lung Cancer
December 2023, Vol 14, No 6
Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer.
Read Article
Phase 3 Trials Show Superiority of Targeted Treatments Over Chemotherapy in Oncogene-Addicted NSCLC
By
William King
Lung Cancer
,
ESMO 2023 Highlights
December 2023, Vol 14, No 6
Madrid, Spain—Results from 3 phase 3 clinical trials demonstrated the superiority of targeted therapies over conventional chemotherapy in patients with oncogene-addicted non–small cell lung cancer (NSCLC), including
ALK
-positive advanced NSCLC;
EGFR
exon 20 insertion-mutation–positive, newly diagnosed or advanced NSCLC; and advanced
RET
fusion–positive NSCLC. These findings were reported during the European Society for Medical Oncology Congress 2023.
Read Article
Gavreto Receives Regular Approval for Patients With RET-Positive NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
October 2023, Vol 14, No 5
On
August 9, 2023
, the FDA granted regular approval to pralsetinib (Gavreto; Genentech), a kinase inhibitor of wild-type
RET
and oncogenic
RET
fusions and mutations, for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) and
RET
fusion–positive gene mutation, as detected by an FDA-approved test.
Read Article
Keytruda Received FDA Approval for Adjuvant Treatment of NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
February 2023, Vol 14, No 1
On
January 26, 2023
, the FDA approved pembrolizumab (Keytruda; Merck), a PD-1 inhibitor, as monotherapy for adjuvant treatment of patients with stage IB (T2a ≥4 cm), II, or IIIA non–small-cell lung cancer (NSCLC), after resection and platinum-based chemotherapy.
Read Article
Krazati Receives Accelerated FDA Approval for NSCLC with KRASᴳ¹²ᶜ Mutation
FDA Approvals, News & Updates
,
Lung Cancer
February 2023, Vol 14, No 1
On
December 12, 2022
, the FDA accelerated the approval of adagrasib (Krazati; Mirati Therapeutics), a RAS GTPase inhibitor, for adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and
KRAS
G12C
mutation (as determined by an FDA-approved test) who have received at least 1 systemic therapy.
Read Article
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic NSCLC
FDA Approvals, News & Updates
,
Lung Cancer
December 2022, Vol 13, No 6
Two weeks after the initial approval of tremelimumab (Imjudo; AstraZeneca), a CTLA-4 monoclonal antibody, on
November 10, 2022
, the FDA approved this new immunotherapy, in combination with the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca) and platinum-based chemotherapy, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and no
EGFR
or
ALK
genomic alterations.
Read Article
Faculty Perspectives Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine
Lung Cancer
Faculty Perspectives Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine
For this supplement, expert faculty provided detailed perspectives based on their extensive experience in the management of non–small cell lung cancer (NSCLC), focusing on the incorporation and importance of biomarker testing in precision medicine for improved patient care.
Read Article
Sotorasib Elicits Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
By
Phoebe Starr
Lung Cancer
August 2022, Vol 13, No 4 Online Only
Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with
KRAS
p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial.
Read Article
Exkivity Receives Accelerated Approval for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approvals, News & Updates
,
Lung Cancer
October 2021, Vol 12, No 5
On September 15, 2021, the FDA accelerated the approval of mobocertinib (Exkivity; Takeda Pharmaceuticals), a tyrosine kinase inhibitor, for the treatment of adults with locally advanced or metastatic non−small-cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by the FDA-approved Oncomine Dx Target Test (Life Technologies Corporation), which was approved on the same day as a companion diagnostic for mobocertinib. The FDA granted mobocertinib priority review, breakthrough therapy designation, and orphan drug designation.
Read Article
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
By
Phoebe Starr
Lung Cancer
October 2021, Vol 12, No 5
Approximately 13% of patients with lung adenocarcinoma harbor the KRAS p.G12C mutation, which is associated with poor clinical outcomes. During the American Society of Clinical Oncology 2021 virtual annual meeting, Ferdinandos Skoulidis, MD, PhD, MRCP, Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, provided updated results from the phase 2 component of the CodeBreaK 100 clinical trial, which evaluated sotorasib (Lumakras), a small-molecule inhibitor of the KRAS p.G12C mutation, in previously treated patients with non–small-cell lung cancer (NSCLC) whose tumors express this aberration. These results were simultaneously published in the New England Journal of Medicine.
Read Article
Page 1 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma